8-K: Akebia Therapeutics Extends Supply Agreement with STA Pharmaceutical, Securing Vadadustat Manufacturing Through 2029

Akebia Therapeutics has extended its supply agreement with STA Pharmaceutical for the manufacturing of vadadustat drug substance by five years, now expiring in 2029, and has also amended the pricing structure.

Summary

• Akebia Therapeutics has amended its supply agreement with STA Pharmaceutical Hong Kong Limited.
• The amendment extends the term of the agreement for an additional five years, with the new expiration date being April 2, 2029.
• The agreement pertains to the manufacturing of vadadustat drug substance for Akebia's commercial purposes.
• The amendment also includes changes to the volume-based pricing structure.

Sentiment

Score: 7

Explanation: The document reflects a positive development for Akebia by securing its supply chain for the next five years. The lack of specific details on the pricing structure prevents a higher score.

Positives

• The extension of the supply agreement ensures a continued supply of vadadustat drug substance for Akebia.
• The five-year extension provides long-term stability for Akebia's manufacturing needs.
• The amended pricing structure may offer more favorable terms for Akebia.

Risks

• The document does not detail the specific changes to the pricing structure, which could potentially impact Akebia's costs.
• The reliance on a single supplier, STA Pharmaceutical, for vadadustat manufacturing could pose a risk if issues arise with that supplier.

Future Outlook

The extended supply agreement ensures the continued manufacturing of vadadustat drug substance through April 2029, providing a stable supply chain for Akebia.

Management Comments

• John P. Butler, President and Chief Executive Officer, signed the report on behalf of Akebia Therapeutics, Inc.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly in the context of supply chain management and contract manufacturing. Securing long-term supply agreements is crucial for companies like Akebia to ensure the availability of their products.

Comparison to Industry Standards

• Long-term supply agreements are common in the pharmaceutical industry to secure manufacturing capacity and manage costs.
• Companies like Catalent and Lonza are major players in contract manufacturing, and Akebia's agreement with STA is similar to arrangements these companies have with their clients.
• The five-year extension is a typical duration for such agreements, providing a balance between stability and flexibility.

Stakeholder Impact

• Shareholders will likely view the extension of the supply agreement positively, as it ensures the continued production of vadadustat.
• The agreement provides stability for Akebia's operations and supply chain.

Next Steps

• Akebia will file the full details of the Amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.

Key Dates

Keywords

Akebia Therapeutics, STA Pharmaceutical, vadadustat, supply agreement, manufacturing, drug substance, contract extension, pricing structure